- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Amgen, Allergan Submit BLA for Proposed Biosimilar Rituximab ABP 798 to FDA
Amgen and Allergan submitted a Biologics License Application (BLA) to the FDA for ABP 798, a biosimilar rituximab referencing Rituxan.
Amgen and Allergan late Thursday announced the submission of a Biologics License Application (BLA) to the FDA for ABP 798, a biosimilar rituximab referencing Rituxan.
"The US filing for ABP 798 marks an important milestone for Amgen, as it affirms our commitment to providing high quality biosimilars that offer more life-altering biological treatment options and contribute to the sustainability of healthcare systems," said David M. Reese, MD, executive vice president of research and development at Amgen, in a statement. "We look forward to working with the FDA to bring ABP 798 to market."
Rituxan is a CD20-directed cytolytic antibody that is approved to treat multiiple diseases, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis with glucocorticoids, and rheumatoid arthritis (RA). While the companies did not say which indications it was pursuing in its statement, the companies referenced the first 4 indications, but not RA.
"We are excited about the progress that we've made to date through our partnership with Amgen, which includes the launch of the first 2 oncology therapeutic biosimilars in the US," said David Nicholson, PhD, chief research and development officer at Allergan. "With ABP 798, we look forward to the opportunity to continue to provide additional treatment options to patients suffering from serious illnesses."
Amgen has a total of 10 biosimilars in its portfolio, 3 of which have been approved by the FDA and 3 that are approved in the European Union (EU).
Amgen and Allergan are collaborating on 4 oncology biosimilar medicines, 2 of which have already been approved by the FDA.
The BLA submission includes analytical, pharmacokinetic and clinical data, as well as pharmacology and toxicology data generated in 2 clinical studies. The results of these studies confirmed no clinically meaningful differences between ABP 798 and Rituxan.
Last month at the American College of Rheumatology (ACR)’s 2019 meeting, researchers reported on a phase 1 and 3 study of ABP 798 in patients with RA.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar
January 31st 2025The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions. It is the third biosimilar to reference Actemra (tocilizumab) to be approved for US patients.
